China-based Genor Biopharma Co., Ltd (HKG: 6998) has entered into a significant licensing and equity agreement with US-based TRC 2004, Inc., bestowing upon TRC 2004 the exclusive rights to develop, manufacture, and commercialize Genor’s innovative drug candidate, GB261, in all global territories excluding Greater China. This strategic partnership is set to bolster Genor’s presence in international markets.
Under the terms of the agreement, Genor is to receive a substantial equity stake in TRC 2004, an upfront payment in the tens of millions of dollars, potential milestone payments reaching up to USD 443 million, and tiered royalties on future net sales, which will vary from single to double-digit percentages.
GB261, a first-in-class CD20/CD3 T-cell engager, has shown promising results in significantly inhibiting the growth of rituximab-resistant cancer cells across in vitro assays and in vivo models. As a B-cell depletion agent, GB261 holds the potential for development in therapeutic areas beyond oncology, including immunological and autoimmune diseases.
TRC 2004, a venture established by renowned VC funds Two River and Third Rock Ventures—latter being instrumental in the founding of Kite Pharma, the developer of the CD19 CAR-T therapy Yescarta—brings a wealth of expertise and resources to the partnership, aiming to maximize the global potential of GB261.- Flcube.com
